ProMIS Neurosciences Past Earnings Performance
Past criteria checks 0/6
ProMIS Neurosciences's earnings have been declining at an average annual rate of -18.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 70.7% per year.
Key information
-18.1%
Earnings growth rate
2.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -70.7% |
| Return on equity | -7.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ProMIS Neurosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -1 | 5 | 6 |
| 30 Jun 24 | 0 | -12 | 4 | 0 |
| 31 Mar 24 | 0 | -12 | 6 | 0 |
| 31 Dec 23 | 0 | -13 | 6 | 0 |
| 30 Sep 23 | 0 | -17 | 8 | 0 |
| 30 Jun 23 | 0 | -20 | 8 | 0 |
| 31 Mar 23 | 0 | -21 | 5 | 0 |
| 31 Dec 22 | 0 | -18 | 6 | 0 |
| 30 Sep 22 | 0 | -13 | 6 | 0 |
| 30 Jun 22 | 0 | -8 | 6 | 0 |
| 31 Mar 22 | 0 | -6 | 5 | 0 |
| 31 Dec 21 | 0 | -10 | 4 | 0 |
| 30 Sep 21 | 0 | -8 | 2 | 0 |
| 30 Jun 21 | 0 | -8 | 1 | 0 |
| 31 Mar 21 | 0 | -9 | 2 | 0 |
| 31 Dec 20 | 0 | -4 | 2 | 0 |
| 30 Sep 20 | 0 | -5 | 2 | 0 |
| 30 Jun 20 | 0 | -5 | 2 | 0 |
| 31 Mar 20 | 0 | -5 | 2 | 0 |
| 31 Dec 19 | 0 | -6 | 2 | 0 |
| 30 Sep 19 | 0 | -7 | 2 | 0 |
| 30 Jun 19 | 0 | -8 | 2 | 0 |
| 31 Mar 19 | 0 | -8 | 2 | 0 |
| 31 Dec 18 | 0 | -7 | 2 | 0 |
| 30 Sep 18 | 0 | -6 | 2 | 0 |
| 30 Jun 18 | 0 | -5 | 2 | 0 |
| 31 Mar 18 | 0 | -5 | 2 | 0 |
| 31 Dec 17 | 0 | -5 | 2 | 0 |
| 30 Sep 17 | 0 | -5 | 2 | 0 |
| 30 Jun 17 | 0 | -4 | 2 | 0 |
| 31 Mar 17 | 0 | -3 | 1 | 0 |
| 31 Dec 16 | 0 | -3 | 1 | 0 |
| 30 Sep 16 | 0 | -2 | 1 | 0 |
| 30 Jun 16 | 0 | -2 | 1 | 0 |
| 31 Mar 16 | 0 | -2 | 1 | 0 |
| 31 Dec 15 | 0 | -2 | 1 | 0 |
| 30 Sep 15 | 0 | -1 | 1 | 0 |
| 30 Jun 15 | 0 | -2 | 1 | 0 |
| 31 Mar 15 | 0 | -2 | 1 | 0 |
| 31 Dec 14 | 0 | -2 | 1 | 0 |
| 30 Sep 14 | 0 | -3 | 1 | 0 |
| 30 Jun 14 | 0 | -2 | 1 | 0 |
| 31 Mar 14 | 0 | -2 | 1 | 0 |
| 31 Dec 13 | 0 | -2 | 1 | -1 |
Quality Earnings: 23J0 is currently unprofitable.
Growing Profit Margin: 23J0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 23J0 is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.
Accelerating Growth: Unable to compare 23J0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 23J0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 23J0 has a negative Return on Equity (-7.75%), as it is currently unprofitable.